NMRC Bone Marrow Program
Closed Special Notice Posted
- Solicitation number
- N3239824Q9982
- Agency
- Naval Supply Systems Command Department of the Navy, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 621511 Medical Laboratories
- Place of performance
- Silver Spring, Maryland 20910, United States
- Points of contact
-
- Deborah Sharpe deborah.m.sharpe2.civ@health.mil (301) 319-9948
- Shamai Carter shamai.m.carter.civ@health.mil (301) 319-7182
Notice details come from SAM.gov. Updated .
About this opportunity
The United States Department of Naval Medical Research Command (NMRC) has issued a Special Notice for a sole-source contract with CareDX Lab Solutions, Inc. to continue research and development of a next-generation sequencing (NGS)-based assay using hybrid capture technology. This assay is intended to assess response to various immunosuppression protocols for hematopoietic stem cell transplant (HSCT) patients.
The purpose of this effort is to optimize the probe design, verify and validate the assay, and initiate the development of interpretation software. The period of performance is from September 2024 to May 2025. NMRC is utilizing the statutory exceptions for other than full and open competition under 10 U.S.C. 2304(c)(1) and 10 U.S.C. 2304(c)(3), as CareDX Lab Solutions, Inc. is the only responsible source with the unique qualifications and capability to perform this research. Interested parties must be registered in the System for Award Management (SAM) and have a Unique Entity Identification (UEI) number to be eligible for award. The contract will be a Firm Fixed Price arrangement, with the pricing determined to be fair and reasonable.
Notice text
The United States Department Of Naval Medical Research Command (NMRC) intends to award a sole source contract, CareDX Lab Solutions., West Chester, PA. 19382. This notice is not a request for competitive proposals however If interested Government shall consider all responses.
The DoD Bone Marrow Program mission in the treatment of radiation and chemical weapon exposure is unique to the Armed Forces. When prescribed 90% of drugs work only in 30-50% this is because 90% of individuals are likely to have different clinically actionable pharmacogenetic genotype. There is a strong and well documented correlation between drug efficacy and variation in genes responsible for drug metabolism or transport (Pharmacogenetics; PGx). Maintaining an optimal level of immunosuppression is critical for successful post-transplant management after HSCT. Too low level of immunosuppression might lead to GvHD and relapse, whereas too high level of immunosuppression might lead to toxicity and deleterious side effects.
Metabolism and efficacy of most commonly used immunosuppressive drugs are modulated by pharmacogenes. Variations in pharmacogenes are widespread across different populations, with many of them frequent in minority groups. Genetic testing allows for identification of patients carrying deleterious variants in pharmacogenes.
The proposed action is the continuation of research to develop an NGS-based assay using hybrid capture technology to assess response to various immunosuppression protocols (drugs) in the surveillance of HSCT patients.
1. Stage 1 Optimization Personnel Hours
2. Stage 1 Optimization Reagents Cost
3. Stage 2 Verification Personnel Hours
4. Stage 2 Verification Reagents Cost
5. Stage 3 Software Development - Initiation phase Personnel hours
Period Of Performance Sep 2024 - May 2025.
The NAICS code for this action is 621511. This requirement will be procured under the guidelines of FAR Part 12 Commercial Items. NMRC requires that all contractors doing business with the Acquisition Office must be registered with the Systems for Award Management (SAM). No award can be made unless the vendor is registered in Systems for Award Management. For additional information and to register in SAM, please access the following website: https://www.sam.gov/. In order to register with the SAM and to be eligible to receive an award from this Acquisition Office, all offers must have a Unique Entity Identification Number (UEI). A Sam.gov number may be acquired free of charge by contacting Sam.gov online at www.sam.gov or by phone at (866) 606-8220. See attached J&A for specifics.
Email your Quote to the following:
shamai.m.carter.civ@health.mil
deborah.m.sharpe2.civ@health.mil
Attachments
| File | Type | Posted |
|---|---|---|
| N3239824Q9982 JAA_Redacted.pdf |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity